On February 19, 2003, NIDA, in collaboration with NCI and NIAAA, will hold a 1-day meeting entitled Smoking Cessation Pharmacotherapy: Accelerating Discovery-to-Delivery. This meeting immediately precedes the annual meeting of the Society for Research on Nicotine and Tobacco.
NIDA will co-sponsor the Cold Spring Harbor Laboratory meeting entitled Whole Genome Mutagenesis Strategies in the Mouse on March 5-6, 2003.
The Club Drugs Workgroup has organized a Symposium, "Club Drugs" Neuropharmacology: New Challenges, to be held as part of the "Experimental Biology 2003" meeting, April 14, 2003, at the San Diego Convention Center. The speakers are Jerry Frankenheim, Ph.D. (The "Club Drugs" Present New Challenges), Bryan K. Yamamoto, Ph.D. (Neurotoxic Amphetamines), John Mendelson, M.D. (Functional Consequences of MDMA Abuse), O. Carter Snead III, M.D. (GHB Physiology and Pharmacology), Gerard J. Marek, M.D., Ph.D. (Hallucinogens: From LSD to Mescaline), and John W. Olney, M.D. (Neurotoxicity of NMDA Antagonists (Ketamine, PCP, N2O, Ethanol) in the Adult and Developing Brain).
NIDA, NINDS, NIMH, and NIAAA will co-sponsor a meeting entitled Genes, Brain, Behavior: Before and Beyond Genomics on April 16, 2003, on the NIH Campus, Wilson Hall, Building 1 as a satellite to celebrate the 50th anniversary of the discovery of the double helix.
NIDA plans to sponsor a workshop with the Human Proteome Organization (HuPO) that will take place in March 2003.
National CTN Steering Committee Meetings are planned for the following dates and locations: March 24-26, 2003, in Albuquerque, NM; June 20-21, 2003, in Fort Lauderdale, FL; and September 10-12, 2003, in Denver, CO.